

DEKALB COUNTY HEALTH DEPARTMENT
2009-2010 NOVEL H1N1 INFLUENZA IMMUNIZATION CLINIC
Vaccine Reference Sheet

TABLE 1 FDA Approved influenza vaccines for different age groups --- United States, Influenza A (H1N1) 2009 Monovalent Vaccine

Vaccine	Manufacturer	Presentation	Mercury content (mcg Hg/0.5 mL dose)	Age group	No. of doses	Route
Inactivated Vaccine	Sanofi Pasteur	0.25mL prefilled syringe (1 dose)	0	6--35 mos*	1 or 2 doses*	Intramuscular
		0.5 mL prefilled syringe (1 dose)	0	≥36 mos*		Intramuscular
		0.5 mL vial (1 dose vial)	0	≥36 mos*		Intramuscular
		5.0 mL multidose vial(10 dose vial)	25 ¹	≥6 mos*		Intramuscular
Inactivated Vaccine	Novartis Vaccine	5.0 mL multidose vial (10 dose vial)	25	≥4 yrs*	1 or 2	Intramuscular
		0.5 mL prefilled syringe (1 dose)	<1.0 (trace)			
Inactivated Vaccine	CSL Biotherapies	0.5 mL prefilled syringe (1 dose)	0	≥18 yrs	1	Intramuscular
		5.0 mL multidose vial (10 dose vial)	24.5			
LAIV	MedImmune	0.2 mL sprayer (1 dose, .1ml per nostril)	0	2--49 yrs**	1 or 2 [†]	Intranasal

*Two doses administered at least 1 month apart are recommended for children aged 6 months through 9 years who are receiving **Influenza A (H1N1) 2009 Monovalent Vaccine**

For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.

** LAIV **Influenza A (H1N1) 2009 Monovalent Vaccine** is shipped refrigerated and stored in the refrigerator at 2°C--8°C (36°F to 46°F) after arrival in the immunization clinic. The dose is 0.2 mL divided equally between each nostril. LAIV **Influenza A (H1N1) 2009 Monovalent Vaccine** should not be administered to persons with asthma. Health-care providers should consult the medical record, when available, to identify children aged 2--4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV **Influenza A (H1N1) 2009 Monovalent Vaccine**, parents or caregivers of children aged 2--4 years should be asked: "In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record during the preceding 12 months should not receive LAIV **Influenza A (H1N1) 2009 Monovalent Vaccine**.

[†]Two doses administered at least 4 weeks apart are recommended for children aged 2--9 years who are receiving LAIV or to children or adults who received seasonal LAIV at any time within the preceding 4 weeks, including the date of the current visit. LAIV **Influenza A (H1N1) 2009 Monovalent Vaccine** should not be administered until 48 hours after antiviral cessation. Antiviral agents should not be administered until 2 weeks after Influenza A (H1N1) 2009 Monovalent Vaccine Live, intranasal administration unless medically necessary.

Inactivated Vaccine will not be given to individuals who state:

1. They are allergic to eggs.
2. They have had a febrile illness within the past 24 hours.
3. They report a history of previous adverse reaction to vaccine components.

In addition to the above stated contraindications for Inactivated Vaccine, there are other contraindications for live vaccine:

LAIV will not be given to individuals >2 years who state:

1. They have any history of wheezing/or asthma
2. They have a disease that decreases their immunity

3. They think they might be pregnant or are pregnant
4. They received seasonal LAIV flu mist within the past 4 weeks

See following web sites for packet inserts that include results of clinical trials.

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181973.htm>

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181975.htm>

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181970.htm>

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181971.htm>